Covid jab maker BioNTech said Monday it would build a southeast Asia headquarters and manufacturing site in Singapore to produce hundreds of millions of mRNA-based vaccines per year. Construction of the site will start this year, and it could become operational by 2023, the German company said in a statement. Bangkok Post

FILE PHOTO: Empty vials of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are seen at The Michener Institute, in Toronto, Canada Jan 4, 2021. (Reuters)

Covid jab maker BioNTech said Monday it would build a southeast Asia headquarters and manufacturing site in Singapore to produce hundreds of millions of mRNA-based vaccines per year.

Construction of the site will start this year, and it could become operational by 2023, the German company said in a statement.

"With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world," said BioNTech chief executive Ugur Sahin.

The vaccine produced by BioNTech jointly with Pfizer of the United States became the first Covid-19 jab to be approved for use in the West late last year.

It is now supplying more than 90 countries worldwide, and is expecting to ramp up its production to up to three billion doses by the end of the year from 2.5 billion doses expected previously.

The pace will further accelerate to more than three billion doses in 2022.

Messenger RNA genetic technology trains the body to reproduce spike proteins, similar to that found on the coronavirus.

When exposed to the real virus later, the body recognises the spike proteins and is able to fight them off.

US pharmaceutical firm Moderna uses the same technology for its vaccine.